1. Home
  2. SSBI vs INKT Comparison

SSBI vs INKT Comparison

Compare SSBI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSBI

Summit State Bank

N/A

Current Price

$13.67

Market Cap

86.7M

Sector

Finance

ML Signal

N/A

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$12.25

Market Cap

70.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSBI
INKT
Founded
1982
2017
Country
United States
United States
Employees
106
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.7M
70.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SSBI
INKT
Price
$13.67
$12.25
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
4.1K
60.1K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.60
$6.66
52 Week High
$14.00
$76.00

Technical Indicators

Market Signals
Indicator
SSBI
INKT
Relative Strength Index (RSI) 57.47 52.14
Support Level $12.78 $10.94
Resistance Level $13.68 $12.58
Average True Range (ATR) 0.19 1.14
MACD 0.01 0.18
Stochastic Oscillator 87.51 37.18

Price Performance

Historical Comparison
SSBI
INKT

About SSBI Summit State Bank

Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: